Group items tagged

The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-18-337).

The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat Substance Use Disorders (SUDs) move through the drug development process. Both the project period and budget of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding. Project aims can range from the development of a new molecular entity to the expansion of an existing medication's clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process. It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The purpose of this announcement is to support and facilitate multidisciplinary approaches to the development of new and/or improved contraceptive methods for both men and women.  This FOA expands the scope of the former program by calling for Centers to inform contraceptive development and improve contraceptive use by integrating the biomedical research and development with behavioral and social science research, e.g., demography and other population sciences, psychology, economics, and sociology.  These Centers also will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

The purpose of this announcement is to support and facilitate multidisciplinary approaches to the development of new and/or improved contraceptive methods for both men and women.  This FOA expands the scope of the former program by calling for Centers to inform contraceptive development and improve contraceptive use by integrating the biomedical research and development with behavioral and social science research, e.g., demography and other population sciences, psychology, economics, and sociology.  These Centers also will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

This Broad Agency Announcement (BAA) seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address Zimbabwe's Development Challenges. Those Development Challenges may include opportunities to increase the number of Zimbabweans who live longer, healthier lives. The United States Agency for International Development (USAID) invites individuals, organizations, and companies to participate with the USAID Mission in Zimbabwe (USAID/Zimbabwe) to create more strategic, focused and results- oriented solutions to respond to the development challenges in Zimbabwe.

This Funding Opportunity Announcement (FOA) encourages applications from investigators that propose to study the developing brain or brain areas that play significant roles in mediating emotional and motivated behavior and in substance use and dependence.  All stages of brain development are of interest, but a new emphasis of the current reissue of this initiative is to support basic neuroscience research on fundamental mechanisms of brain development during prepuberty and the adolescent period in relation to the problems of substance abuse and co-morbidity with psychiatric disorders.  Topics of interest pertaining to brain development of this initiative include, but are not limited to, the euphoric properties of abused substances, actions of psychotherapeutic agents, and their consequences on memory, cognitive and emotional processes.  A major goal of this initiative is to understand how exposure to substances of abuse and environmental insults affects the cellular and molecular mechanisms underlying nervous system development and neural circuit functions implicated in substance use and addiction. 

This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications from institutions/organizations that propose to study the developing brain or brain areas that play significant roles in mediating emotional and motivated behavior and in substance use and dependence. All stages of brain development are of interest, but a new emphasis of the current reissue of this initiative is to support basic neuroscience research on fundamental mechanisms of brain development during prepuberty and the adolescent period in relation to the problems of substance abuse and co-morbidity with psychiatric disorders. Topics of interest pertaining to brain development of this initiative include, but are not limited to, the euphoric properties of abused substances, actions of psychotherapeutic agents, and their consequences on memory, cognitive and emotional processes. An additional major goal of this initiative is to understand how exposure to substances of abuse affects the cellular and molecular mechanisms underlying nervous system development and neural circuit functions implicated in substance use and addiction.

The FY18 PH/TBIRP CTRR-CTDA mechanism is being offered for the first time in FY18 and is intended to support the development of clinical trials focused on TBI rehabilitation interventions in the FY18 PH/TBIRP CTRR-CTDA focus areas described in II.A.1. Development of clinical trials focusing on rehabilitation strategies in patients with mild TBI is highly encouraged. The proposed research must be relevant to active duty Service members, Veterans, and their beneficiaries. It is expected that any research findings will also provide benefit to the general population. The PH/TBIRP CTRR-CTDA mechanism supports the design and development of the research resources necessary to serve as a foundation for investigator-initiated clinical trials under future PH/TBIRP CTRR-Clinical Trial Award with the potential to develop knowledge and material products for rehabilitation and restoration of function following TBI. Principal Investigators (PIs) should explain how the proposed future clinical trial will inform the development, refinement, and/or revision of existing standards of care, clinical recommendations, or guidelines.

The Science of Science & Innovation Policy (SciSIP) program supports research designed to advance the scientific basis of science and innovation policy. Research funded by the program thus develops, improves and expands models, analytical tools, data and metrics that can be applied in the science policy decision making process. For example, research proposals may develop behavioral and analytical conceptualizations, frameworks or models that have applications across a broad array of SciSIP challenges, including the relationship between broader participation and innovation or creativity. Proposals may also develop methodologies to analyze science and technology data, and to convey the information to a variety of audiences. Researchers are also encouraged to create or improve science and engineering data, metrics and indicators reflecting current discovery, particularly proposals that demonstrate the viability of collecting and analyzing data on knowledge generation and innovation in organizations. Among the many research topics supported are:examinations of the ways in which the contexts, structures and processes of science and engineering research are affected by policy decision, the evaluation of the tangible and intangible returns from investments in science and from investments in research and development, the study of structures and processes that facilitate the development of usable knowledge, theories of creative processes and their transformation into social and economic outcomes, the collection, analysis and visualization of new data describing the scientific and engineering enterprise. The SciSIP program invites the participation of researchers from all of the social, behavioral and economic sciences as well as those working in domain-specific applications such as chemistry, biology, physics, or nanotechnology. The program welcomes proposals for individual or multi-investigator research projects, doctoral dissertation improvement awards, conferences, wo

This cooperative agreement will establish and maintain an interdisciplinary, multicenter research forum for scientific collaboration and infrastructure building, which will provide national leadership in research designed to improve the behavioral, mental, social, and/or cognitive health and wellbeing of children and adolescents with Autism Spectrum Disorder (ASD) and other developmental disabilities. As authorized by Section 399BB of the Autism CARES Act, the research network will determine the evidence-based practices for interventions to improve the behavioral health of individuals with ASD and other developmental disabilities, develop guidelines for those interventions, and disseminate information related to such research and guidelines. The AIR-B Network will be one of two HRSA-supported research networks that will provide national leadership in research to advance the evidence base on effective interventions for children and adolescents with ASD and other developmental disabilities, with AIR-B having a focus on addressing behavioral health and wellbeing. As directed by the FY 2015 Congressional Appropriations for HRSA's Autism CARES Act programs, HRSA is broadening the scope of this funding opportunity to reflect an additional emphasis on addressing disparities in effective interventions and treatment and access to care experienced by underserved minority and rural communities. In particular, applicants should consider diverse ethnic/racial, cultural, linguistic, socioeconomic, and geographic (e.g., rural/urban, tribal) populations for whom there is little evidence regarding the effectiveness of interventions, or for whom access to effective treatments is limited. Applicants should include plans to conduct multi-site research protocols on innovative treatment models, including the use of telehealth networks, to improve behavioral health interventions and treatment for ASD in underserved minority and rural communities. It is expected that the AIR-B Netwo

This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I- Corps™ program is being offered. The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will provide administrative supplement awards to two cohorts of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps™ at NIH Program. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I- Corps™ program is being offered. The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will provide administrative supplement awards to two cohorts of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps™ at NIH Program. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

The purpose of the Institutional Research and Academic Career Development Award (IRACDA) Program is to develop a diverse group of highly trained biomedical and behavioral scientists to address the Nation's biomedical workforce needs. The strategy is to promote effective partnerships between research-intensive institutions (RII) and institutions that have a historical mission or a demonstrated commitment to educating students from diverse backgrounds underrepresented in the biomedical and behavioral research enterprise of the nation. The IRACDA program provides support for a traditional mentored postdoctoral research experience at an RII combined with an opportunity for these fellows to develop critical academic skills, including teaching, through workshops and through mentored teaching assignments at a partner institution. The primary goals of the IRACDA program are to (1) develop a group of highly trained biomedical and behavioral scientists who have the necessary knowledge and skills to pursue independent research and teaching careers in academia; and (2) strengthen and modernize science educational offerings at partner institutions, and promote links between RII and the partner institution(s). 

The goal of this funding opportunity announcement (FOA) is to provide a global outline of areas for innovative, targeted basic behavioral and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas. This FOA encourages research designed to (a) conduct basic behavioral and social science research that is needed to advance the development of HIV prevention and care interventions, (b) translate and operationalize the findings from these basic studies to develop interventions and assess their feasibility and (c) conduct tests of the efficacy of HIV prevention and care interventions. The R21 mechanism is specifically intended to encourage new exploratory and developmental research projects. These studies should break new ground or extend previous discoveries toward new directions or applications. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel methodologies, tools, technologies, or interventions that could have a major impact on health research and practice. Unlike applications under the R01 mechanism, preliminary data are not required for R21 applications. Preliminary data may nonetheless be included if available.

The Army Contracting Command - New Jersey (ACC-NJ), on behalf of The Department of Defense (DOD) is releasing this special notice to inform interested parties of an interest in establishing a Section 845 Other Transaction (OTA) agreement with an eligible entity or group of entities to develop and mature technologies and support policy development to enable advanced approaches to electromagnetic spectrum use. This initiative will support possible needs across the government and industry, in alignment with the National Information Technology R&D (NITRD)/Wireless Spectrum R&D (WSRD) Senior Steering Group (SSG) mission to promote collaboration among government, industry and academia. The purpose of this effort is to identify areas of Research & Development/Prototyping (R&D/PROTOTYPING) of vital importance to the Department's ability to maintain access to the Electromagnetic Spectrum (EMS). The Government is seeking to facilitate optimal application of SRF funds in developing technologies that enable both spectrum sharing and more efficient spectrum use.

The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement.

The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline. This project is part of the NIH initiative to establish a public-private partnership to address the opioid crisis via more effective and safe ways to prevent and treat opioid use disorders and overdose. https://www.nih.gov/opioid-crisis

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity. Novel and augmented techniques are sought that will ultimately be broadly accessible to the neuroscience community for the interrogation of microconnectivity in healthy and diseased brains of model organisms and humans. Development of technologies that will significantly drive down the cost of connectomics would enable routine mapping of the microconnectivity on the same individuals that have been analyzed physiologically, or to compare normal and pathological tissues in substantial numbers of multiple individuals to assess variability.  Advancements in both electron microscopy (EM) and super resolution light microscopic approaches are sought. Applications that propose to develop approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. Proof-of-principle demonstrations and/or reference datasets enabling future development are welcome, as are improved approaches for automated segmentation and analysis strategies of neuronal structures in EM images.

The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.

Society for Research in Child Development Victoria S. Levin Grant The grant serves the promising pre-tenured, junior investigator by: 1. Supporting release time from duties during which time the grantee writes and submits an application in the area of early childhood mental health to the NIH. This support compensates the grantee's unit/department for the work from which the grantee is released. Having adequate time to develop and submit a grant application is essential for early career success. 2. Providing travel funds for a trip to NIH to meet program staff. This support helps the grantee develop meaningful contacts with NIH program staff who can guide the application preparation and revision (funding usually requires two application submissions). 3.Providing a pre-review of the candidate's NIH application. This support allows the mentor and grantee to benefit from an external critique of the NIH application prior to its submission. In our experience, this pre-review heightens the chances of early success in the first round of review and the mentor is able to guide the grantee in responding to reviews. Aiming to heighten the chances of early success in achieving federal funding for developmentally-informed research that addresses the early foundations of children's mental health and well-being, the Victoria S. Levin Grant for Early Career Success in Young Children's Mental Health Research was created to honor and carry forward this focus of Victoria S. Levin's life work.